NASDAQ · INDP
Indaptus Therapeutics, Inc.
$3.38+$0.04 (+1.2%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.29% below the high.
Loading market information…
NASDAQ · SLXN · USD
Stock price, earnings
Quote as of Oct 30, 2026, 01:39 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Silexion Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 99.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Silexion Therapeutics Ltd.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$9.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Silexion Therapeutics Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:43 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 18, 2025 |
| -$115.50+21.43% vs estimate |
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$1,110.00-0.27% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.38+$0.04 (+1.2%)
Indaptus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 43.29% below the high.
$0.52-$0.01 (-2.16%)
Jasper Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.01% below the high.
$1.46+$0.00 (0.0%)
Enveric Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.98% below the high.
$0.84+$0.19 (+29.23%)
Salarius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.41% below the high.
$0.69-$0.07 (-8.73%)
Azitra, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.94% below the high.
$0.56-$0.03 (-4.42%)
Onconetix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.7% below the high.
$0.65-$0.01 (-1.07%)
Protagenic Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.76% below the high.
$0.67-$0.05 (-6.46%)
SciSparc Ltd.’s quoted price sits in the lower half of its reported 52-week range, 97.82% below the high.
